J. Novartis, . Celgene, :. Consultant, ;. Bristol-myers-squibb, :. Gc:-honoraria et al., Funding support and drug supply were provided by F. Hoffmann La Roche Ltd and Celgene Corporation, Independent Data Monitoring Committee (André Bosly, Catherine Sebban, and Natacha Heutte); and all the investigators

. Slg:-honoraria:-roche, . Janssen, . Celgene, . Servier, A. Gilead et al., A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma, Consultant: Janssen, Keocyt et Sanofi; FM: Advisory Board, vol.23, pp.4127-4164, 2017.

T. E. Witzig, J. M. Vose, P. L. Zinzani, C. B. Reeder, R. Buckstein et al., An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell nonHodgkin's lymphoma, Ann Oncol, vol.22, pp.1622-1629, 2011.

M. Trn?ný, T. Lamy, J. Walewski, D. Belada, J. Mayer et al., Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial, Lancet Oncol, vol.17, pp.559-567, 2016.

L. Arcaini, T. Lamy, J. Walewski, D. Belada, J. Mayer et al., Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma, Br J Haematol, vol.180, pp.224-259, 2018.

F. A. Morschhauser, G. Cartron, C. Thieblemont, P. Solal-céligny, C. Haioun et al., Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study, J Clin Oncol, vol.31, pp.2912-2921, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01704593

J. P. Leonard, S. Jung, J. J. Pitcher, B. N. Bartlett, N. L. Blum et al., Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance), J Clin Oncol, vol.33, pp.3635-3675, 2015.

P. Martin, S. Jung, B. Pitcher, N. L. Bartlett, K. A. Blum et al., A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance), Ann Oncol J Eur Soc Med Oncol, vol.28, pp.2806-2818, 2017.

M. Wang, L. Fayad, N. Wagner-bartak, L. Zhang, F. Hagemeister et al., Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial, Lancet Oncol, issue.12, pp.70200-70200, 2012.

J. Ruan, P. Martin, B. Shah, S. J. Schuster, S. M. Smith et al., Lenalidomide plus rituximab as initial treatment for mantlecell lymphoma, N Engl J Med, vol.373, pp.1835-1879, 2015.

P. L. Zinzani, C. Pellegrini, L. Gandolfi, V. Stefoni, F. Quirini et al., Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial, Clin Lymphoma Myeloma Leuk, 2011.

V. Ivanov, D. Coso, B. Chetaille, B. Esterni, D. Olive et al., Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large Bcell lymphoma, Leuk Lymphoma, 2014.

M. Wang, N. Fowler, N. Wagner-bartak, L. Feng, J. Romaguera et al., Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial, Leukemia, 2013.

P. L. Zinzani, C. Pellegrini, L. Argnani, and A. Broccoli, Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab, Haematologica, vol.101, pp.385-391, 2016.

F. Morschhauser, G. Salles, L. Gouill, S. Tilly, H. Thieblemont et al., An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma, Blood, 2018.

B. D. Cheson, S. J. Horning, B. Coiffier, M. A. Shipp, R. I. Fisher et al., J Clin Oncol, p.10561185

M. Crump, S. S. Neelapu, U. Farooq, E. Van-den-neste, J. Kuruvilla et al., Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study, Blood, vol.130, pp.1800-1808, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01829026

U. Vitolo, M. Trn?ný, D. Belada, J. M. Burke, A. M. Carella et al., Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma, J Clin Oncol, vol.35, 2017.